ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years
Vishnu Muthuraj Kumarasamy
Matched on ORCID iD 0009-0008-2021-0730; OpenAlex author ID A5031716277. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 5
- Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-025-02408-5↗
- The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-2504↗
- Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. First author DOI 10.1136/gutjnl-2020-321000↗
- Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. Co-author DOI 10.1038/s41388-019-1102-1↗
- Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. First author DOI 10.1038/s41388-018-0650-0↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Erik S. Knudsen · 5 shared papers, 2019–2025 · strength 0.79
- Paper Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. DOI 10.1186/s12943-025-02408-5↗
- Paper The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer. DOI 10.1158/0008-5472.can-23-2504↗
- Paper Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in … DOI 10.1038/s41388-019-1102-1↗
- Agnieszka Katarzyna Witkiewicz · 5 shared papers, 2019–2025 · strength 0.79
- Paper Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. DOI 10.1186/s12943-025-02408-5↗
- Paper The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer. DOI 10.1158/0008-5472.can-23-2504↗
- Paper Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in … DOI 10.1038/s41388-019-1102-1↗
- Ethan V. Abel · 2 shared papers, 2024–2025 · strength 0.44
- Kennedy S. Humphrey · 1 shared paper, 2025 · strength 0.23
- Katherine J. Crawford · 1 shared paper, 2025 · strength 0.23
- Michael E. Feigin · 1 shared paper, 2025 · strength 0.23
- Karen M. Mann · 1 shared paper, 2025 · strength 0.23
- Prasenjit Dey · 1 shared paper, 2024 · strength 0.21
- Sejin Chung · 2 shared papers, 2019–2021 · strength 0.20
- Paper Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. DOI 10.1136/gutjnl-2020-321000↗
- Paper Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of p… DOI 10.1038/s41388-018-0650-0↗
- Taylor Sohn Riall · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.